Patents by Inventor Joerg Thomas

Joerg Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ANG2 ANTIBODIES AND METHODS OF USE
    Publication number: 20170247441
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Application
    Filed: May 10, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
  • ANTI-PDGF-B ANTIBODIES AND METHODS OF USE
    Publication number: 20170247440
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser
  • BISPECIFIC ANTIBODIES AND METHODS OF USE IN OPHTHALMOLOGY
    Publication number: 20170240629
    Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Olaf Mundigl, Joerg Thomas Regula, Ralf Schumacher, Barbara Weiser
  • BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20170240626
    Abstract: The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: October 4, 2016
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Kay-Gunnar Stubenrauch, Markus Thomas
  • Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
    Patent number: 9724425
    Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: August 8, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Beat Amrein, Stefan Foser, Kurt Lang, Friedrich Metzger, Joerg Thomas Regula, Andreas Schaubmar, Friederike Hesse, Klaus-Peter Kuenkele, Martin Lanzendoerfer
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 9708396
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170190783
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: July 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christianne Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
    Patent number: 9695233
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: July 4, 2017
    Assignee: ROCHE GLYCART AG
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170174786
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: June 22, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Pablo Umana, Sylvia Herter, Christiane Neumann
  • Bispecific antigen binding proteins
    Patent number: 9676845
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: June 13, 2017
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
  • Bispecific T cell activating antigen binding molecules
    Publication number: 20170114146
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Tanja Fauti, Charles Dumontet, Pablo Umana, Marina Bacac, Anne Freimoser-Grundschober
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170096485
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Gerhard NIEDERFELLNER, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20170096495
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: September 29, 2016
    Publication date: April 6, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Thomas HOFER, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Tapan NAYAK, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMAÑA, Tina WEINZIERL
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20170029493
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 12, 2016
    Publication date: February 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • SPR-BASED BRIDGING ASSAY FORMAT FOR DETERMINING THE BIOLOGICAL ACTIVITY OF MULTIVALENT, MULTISPECIFIC MOLECULES
    Publication number: 20170003295
    Abstract: Herein is reported the use of a binding assay of a bivalent, bispecific antibody that has the smaller kD value (dissociation constant) for the interaction with its antigen for the immobilization of the bivalent, bispecific antibody to a solid surface for the determination of the biological activity of the bivalent, bispecific antibody.
    Type: Application
    Filed: June 13, 2016
    Publication date: January 5, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Apollon Papadimitriou, Joerg Thomas Regula, Hubert Kettenberger, Joerg Moelleken, Christian Gassner
  • ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
    Publication number: 20160200833
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: March 10, 2016
    Publication date: July 14, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Victor Levitsky, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • FC-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE
    Publication number: 20160194389
    Abstract: The present invention relates to antibodies and Fc-region fusion polypeptides which are asymmetrically modified with respect to their Fc-receptor, especially their FcRn, and methods of using the same.
    Type: Application
    Filed: October 29, 2015
    Publication date: July 7, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Joerg Thomas Regula, Wolfgang Schaefer, Tilman Schlothauer
  • Multispecific antibodies comprising full length antibodies and single chain fab fragments
    Patent number: 9382323
    Abstract: The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: July 5, 2016
    Assignee: Roche Glycart AG
    Inventors: Ulrich Brinkmann, Peter Bruenker, Rebecca Croasdale, Christian Klein, Erhard Kopetzki, Ekkehard Moessner, Joerg Thomas Regula, Juergen Michael Schanzer, Jan Olaf Stracke, Pablo Umana
  • HUMAN FCRN-BINDING MODIFIED ANTIBODIES AND METHODS OF USE
    Publication number: 20160159894
    Abstract: Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 9, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
  • FCRN-BINDING ABOLISHED ANTI-IGF-1R ANTIBODIES AND THEIR USE IN THE TREATMENT OF VASCULAR EYE DISEASES
    Publication number: 20160151487
    Abstract: The invention provides anti-IGF-1R antibodies with abolished FcRn-binding and methods of using the same for the treatment of vascular eye diseases.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 2, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Guido Hartmann, Joerg Thomas Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer